Ceftazidime for respiratory infections

Abstract

Although ceftazidime remains an important option for HAP treatment, its role as an effective antimicrobial agent has been compromised by the sharp increase in resistance rates over the last decade, especially in P. aeruginosa and Acinetobacter baumannii. To maintain or improve the clinical use of ceftazidime in patients with severe HAP, it will be essential to gain a thorough understanding of local resistance patterns, reserve ceftazidime use when pathogens are susceptible to other third-generation cephalosporins, optimize ceftazidime therapy using prolonged or continuous infusion, determine the effectiveness of the combination of ceftazidime with inhibitors of broad-spectrum β-lactamases and role of combination therapy for P. aeruginosa infections, and judiciously use antimicrobial agents through individualization of antimicrobial therapy for HAP.

Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis – an observational study

“…Ceftazidime is a valuable alternative for the management of nosocomial-acquired pneumonia; nevertheless, its role as an effective antimicrobial agent has decreased over the past decade due to the strong increase in resistance rates, especially for Pseudomonas aeruginosa and Acinetobacter baumannii [ 35 ]. Pseudomonas was not the focus of the investigation in the present research, but an increasing development of antibiotic resistance of S. marcescens and P. mirabilis against ceftazidime was observed.…”